Table 4 Univariate analysis of prognostic factors for difference in bone density in HU
After 3 months | After 6 months | |||||||
|---|---|---|---|---|---|---|---|---|
n | Mean | SD | p-value | n | Mean | SD | p-value | |
Bisphosphonates after RT | p = .069 | p = .162 | ||||||
Yes | 123 | 152.6 | 141.9 | 76 | 245.8 | 151.5 | ||
No | 12 | 76.0 | 86.1 | 9 | 171.9 | 114.4 | ||
Pathological fracture before RT | p = .013 | p = .801 | ||||||
Yes | 29 | 202.3 | 161.9 | 21 | 230.8 | 141.7 | ||
No | 106 | 130.3 | 129.2 | 64 | 240.3 | 152.6 | ||
Pathological fracture after RT | p = .399 | p = .399 | ||||||
Yes | 8 | 186.3 | 133.6 | 8 | 280.5 | 135.3 | ||
No | 127 | 143.2 | 139.9 | 77 | 233.5 | 150.7 | ||
Chemotherapy before RT | p = .946 | p = .991 | ||||||
Yes | 46 | 144.7 | 135.3 | 23 | 238.3 | 172.9 | ||
No | 89 | 146.4 | 148.6 | 62 | 237.8 | 140.9 | ||
Chemotherapy after RT | p = .741 | p = .547 | ||||||
Yes | 72 | 149.5 | 130.9 | 45 | 247.2 | 144.9 | ||
No | 63 | 141.5 | 149.5 | 40 | 227.5 | 154.9 | ||
Endocrine therapy before RT | p = .211 | p = .133 | ||||||
Yes | 47 | 125.2 | 137.3 | 25 | 200.2 | 136.1 | ||
No | 88 | 156.8 | 140.1 | 60 | 253.7 | 152.6 | ||
Endocrine therapy after RT | p = .536 | p = .657 | ||||||
Yes | 26 | 121.9 | 98.1 | 17 | 196.3 | 143.6 | ||
No | 4 | 87.8 | 125.4 | 2 | 250.0 | 316.8 | ||
Pain as indication for RT | p = .822 | p = .963 | ||||||
Yes | 69 | 148.5 | 141.5 | 46 | 238.7 | 143.3 | ||
No | 66 | 143.0 | 138.3 | 39 | 237.1 | 157.7 | ||
Instability as indication for RT | p = .479 | p = .554 | ||||||
Yes | 91 | 139.9 | 133.9 | 57 | 231.2 | 141.9 | ||
No | 44 | 158.1 | 150.9 | 28 | 251.7 | 164.8 | ||
Surgical corset | p = .358 | p = .213 | ||||||
Yes | 82 | 136.9 | 134.9 | 52 | 221.8 | 144.6 | ||
No | 53 | 159.6 | 146.3 | 33 | 263.4 | 154.9 | ||
Spine | p = .437 | p = .858 | ||||||
Thoracic | 99 | 150.7 | 149.1 | 65 | 239.6 | 155.9 | ||
Lumbar | 36 | 132.3 | 109.2 | 20 | 232.7 | 128.1 | ||
Number of metastases | p = .983 | p = .382 | ||||||
1 | 59 | 146.1 | 132.4 | 35 | 254.9 | 158.2 | ||
>1 | 76 | 145.6 | 145.5 | 50 | 226.1 | 142.9 | ||
Overall dose | p = .886 | p = .654 | ||||||
<=30 Gy | 79 | 145.1 | 130.9 | 57 | 229.6 | 143.8 | ||
>30 Gy | 54 | 141.6 | 150.8 | 26 | 245.6 | 162.9 | ||
KPS | p = .815 | p = .412 | ||||||
</=70% | 40 | 150.1 | 148.1 | 23 | 263.4 | 259.9 | ||
>70% | 95 | 143.9 | 136.4 | 62 | 228.5 | 163.7 | ||
Estrogen receptor status | p = .278 | p = .828 | ||||||
Positive | 28 | 139.9 | 115.2 | 19 | 222.5 | 156.6 | ||
Negative | 6 | 83.8 | 99.3 | 2 | 250.0 | 316.8 | ||
Progesterone receptor status | p = .088 | p = .694 | ||||||
Positive | 40 | 159.9 | 123.5 | 25 | 242.7 | 149.5 | ||
Negative | 10 | 87.8 | 83.4 | 4 | 276.5 | 214.5 | ||
Her-2/neu receptor status | p = .581 | p = .379 | ||||||
Positive | 39 | 156.3 | 118.4 | 28 | 220.2 | 108.2 | ||
Negative | 96 | 141.5 | 147.5 | 57 | 246.7 | 165.8 | ||